Prenetics Global Ltd
PRE
查看详细走势图
18.380USD
+0.900+5.15%
收盘 12/22, 16:00（美东）报价延迟15分钟
236.99M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.15%
5天
+25.63%
1月
+44.95%
6月
+105.13%
今年开始到现在
+216.90%
1年
+225.60%
查看详细走势图
TradingKey Prenetics Global Ltd股票评分
单位: USD 更新时间: 2025-12-22操作建议
Prenetics Global Ltd当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名91/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价31.00。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Prenetics Global Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
31.000
目标均价
+116.48%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Prenetics Global Ltd亮点
亮点风险
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
业绩高增长
公司营业收入稳步增长，连续3年增长132.61%
业绩增长期
公司处于发展阶段，最新年度总收入30.62M美元
估值低估
公司最新PE估值-5.19，处于3年历史低位
机构减仓
最新机构持股1.16M股，环比减少52.49%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值26.22K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.14
Prenetics Global Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Prenetics Global Ltd简介
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
公司代码PRE
公司Prenetics Global Ltd
CEOKwok (Samantha)
网址https://ir.prenetics.com/
常见问题
Prenetics Global Ltd(PRE)的当前股价是多少？
Prenetics Global Ltd(PRE)的当前股价是 18.380。
Prenetics Global Ltd的股票代码是什么？
Prenetics Global Ltd的股票代码是PRE。
Prenetics Global Ltd股票的52周最高点是多少？
Prenetics Global Ltd股票的52周最高点是17.990。
Prenetics Global Ltd股票的52周最低点是多少？
Prenetics Global Ltd股票的52周最低点是3.095。
Prenetics Global Ltd的市值是多少？
Prenetics Global Ltd的市值是236.99M。
Prenetics Global Ltd的净利润是多少？
Prenetics Global Ltd的净利润为-46.30M。
现在Prenetics Global Ltd(PRE)的股票是买入、持有还是卖出？
根据分析师评级，Prenetics Global Ltd(PRE)的总体评级为买入，目标价格为31.000。
Prenetics Global Ltd(PRE)股票的每股收益（EPS TTM）是多少
Prenetics Global Ltd(PRE)股票的每股收益（EPS TTM）是-3.544。
相关品种
